A
Alexandre Avila
Researcher at Bristol-Myers Squibb
Publications - 13
Citations - 1988
Alexandre Avila is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 9, co-authored 13 publications receiving 1418 citations.
Papers
More filters
Journal ArticleDOI
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein Abdul-Hassan Tawbi,Peter A. Forsyth,Alain Algazi,Omid Hamid,F. Stephen Hodi,Stergios J. Moschos,Nikhil I. Khushalani,Karl D. Lewis,Christopher D. Lao,Michael A. Postow,Michael B. Atkins,Marc S. Ernstoff,David A. Reardon,Igor Puzanov,Ragini R. Kudchadkar,Reena Thomas,Ahmad A. Tarhini,Ahmad A. Tarhini,Anna C. Pavlick,Joel Jiang,Alexandre Avila,Sheena Demelo,Kim Margolin +22 more
TL;DR: Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases.
Journal ArticleDOI
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Jennifer L. McQuade,Carrie R. Daniel,Kenneth R. Hess,Carmen Mak,Daniel Y. Wang,Rajat Rai,John J. Park,Lauren E. Haydu,Christine N. Spencer,Matthew Wongchenko,Stephen R. Lane,Dung Yang Lee,Mathilde Kaper,Meredith Ann McKean,Kathryn E. Beckermann,Samuel M. Rubinstein,Isabelle Rooney,Luna Musib,Nageshwar Budha,Jessie Hao-Ru Hsu,Theodore S. Nowicki,Alexandre Avila,Tomas Haas,Maneka Puligandla,Sandra J. Lee,Shenying Fang,Jennifer A. Wargo,Jeffrey E. Gershenwald,Jeffrey E. Lee,Patrick Hwu,Paul B. Chapman,Jeffrey A. Sosman,Dirk Schadendorf,Jean-Jacques Grob,Keith T. Flaherty,Dana Walker,Yibing Yan,Edward McKenna,Jeffrey J. Legos,Matteo S. Carlino,Matteo S. Carlino,Antoni Ribas,John M. Kirkwood,Georgina V. Long,Douglas B. Johnson,Alexander M. Menzies,Michael A. Davies +46 more
TL;DR: In patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy.
Journal ArticleDOI
Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer
Tanya J. Williams,David R. Benavides,Kelly Ann Patrice,Josep Dalmau,Alexandre Avila,Dung T. Le,Evan J. Lipson,John C. Probasco,Ellen M. Mowry +8 more
TL;DR: Early recognition and treatment of autoimmune encephalitis in patients receiving immune checkpoint blockade therapy will likely be essential for maximizing clinical recovery and minimizing the effect of drug-related toxic effects.
Journal ArticleDOI
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
James Larkin,Bartosz Chmielowski,Christopher D. Lao,F. Stephen Hodi,William H. Sharfman,Jeffrey S. Weber,Karijn P M Suijkerbuijk,Sergio J Azevedo,Hewei Li,Daniel Reshef,Alexandre Avila,David A. Reardon +11 more
TL;DR: Both oncologists and neurologists need to be aware of signs and symptoms of serious but uncommon neurologic irAEs associated with checkpoint inhibitors and be able to provide prompt treatment of this uncommon, but potentially serious, class of adverse events.
Journal ArticleDOI
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
Hussein Abdul-Hassan Tawbi,Peter A. Forsyth,Alain Algazi,Omid Hamid,F. Stephen Hodi,Stergios J. Moschos,Nikhil I. Khushalani,Rene Gonzalez,Christopher D. Lao,Michael A. Postow,Michael B. Atkins,Marc S. Ernstoff,Igor Puzanov,Ragini R. Kudchadkar,Reena Thomas,Ahmad A. Tarhini,Joel Jiang,Alexandre Avila,Sheena Demelo,Kim Margolin +19 more
TL;DR: The first efficacy data in MEL patients (pts) with BMts who received NIVO+IPI in study CheckMate 204 are reported, and updated safety for 75 pts with disease assessment before the Nov 2016 database lock is reported.